Lilly Asia Ventures has secured a $40m commitment for its fifth biosciences fund, LAV Biosciences V, from San Francisco’s city and county pension fund.

Ascletis has led new strategic partner 3-V Biosciences' $18m series E round, which included existing investors New Enterprise Associates and Kleiner Perkins.

Spun out of Inesc Tec under a strategic agreement with Frontier IP, Insignals hopes to commercialise a surgical guidance device for brain implants to treat conditions including Parkinson's.

David Schenkein is GV's latest general partner and will focus on life sciences while retaining a chairman position at oncology therapy developer Agios Pharmaceuticals.

The corporate venturing units of Semapa and KPN have contributed to Armilar's TechTransfer Fund, which has raised almost $51m on its way to a target of about $68m.

Nuvaira, based on research by a then-professor at Washington University School of Medicine, has closed a $79m funding round led by US Venture Partners.

Kaust is preparing for the third phase of its Taqadam startup accelerator, which is supported by a host of Saudi Arabian academic institutions and claims to have achieved a 35% female participation rate.

Chinese Academy of Sciences invested in a round that will be used to take Haihe's anti-tumour therapies further down the clinical path.

CSPC Pharmaceutical Group and Daehwa Pharmaceutical both invested in a round that will be used to take Haihe's anti-tumour therapies further down the clinical path.

GE’s chief innovation officer and GE Ventures’ CEO, Sue Siegel, has been appointed by Illumina to sit on its board of directors.